Methods and compositions for modulating apolipoprotein (a) expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
Claims20
A compound, or a salt thereof, comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 3900 to 3919 of SEQ ID NO:
- 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.